Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer
Anal Canal Squamous Cell Carcinoma
Explore 8 assets in Anal Canal Squamous Cell Carcinoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Bicara Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04429542CT.gov Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anal Canal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer (this asset) | Bicara Therapeutics | P1 | CC · 43 |
| Retifanlimab | Incyte Corporation | P3 | BB |
| Carboplatin | Incyte Corporation | P3 | BB |
| Nivolumab | National Cancer Institute (NCI) | P3 | BB |
| Fluorouracilum | National Cancer Institute (NCI) | P2 | B |
| Cis-Diamminedichloroplatinum Ii | M.D. Anderson Cancer Center | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Capecitabine | National Cancer Institute (NCI) | P2 | CCC |
| Fludeoxyglucose | National Cancer Institute (NCI) | P2 | CCC |
+3 more in the Anal Canal Squamous Cell Carcinoma cohort
Other indications for Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Squamous Cell Lung Carcinoma | — | P1 | CC · 43 |
| Skin Squamous Cell Carcinoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer in Anal Canal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-de-c-terminal-lysine-anti-human-epidermal-growth-factor-receptor-human-mus-musculus-clone-bca101-1-chain-disulfide-with-human-mus-musculus-clone-bca101-chain-fusion-protein-with-peptide-linker-ggggs3-fusion-protein-with-23-159-transforming-growth-factor-receptor-tgfbr2-human-dimer-anal-canal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →